ORIGINAL PAPER
Objective assessment of the effectiveness of etanercept treatment in patients with juvenile idiopathic arthritis
Online publication date: 2010-07-02
Reumatologia 2010;48(3):177-182
KEYWORDS
ABSTRACT
Objective: Objective assessment the effectiveness of treatment with etanercept in patients with juvenile idiopathic arthritis (JIA) is the aim of this study.
Material and methods: The study was conducted on 33 children before and after switching to etanercept treatment in periods: after 6 months (33 children), after 1 year (24 children), after 1.5 years (18 children) and after 2 years (13 children). Index Disease Activity Score DAS28, a method of diagnostic survey and a systematic analysis of medical records of patients who were enrolled in the biological treatment program were used to examine.
Results: The analysis showed that prior to treatment the children suffering from JIA revealed a significantly higher average level of disease activity (X = 5.82 ±0.77) than in the 6 month period of treatment (X = 2.65 ±1.03) (t = 22.48, p < 0.001). In addition, it has been demonstrated that disease activity of children with JIA after six months of biological treatment (X = 3.33 ±0.77), was significantly lower than after 1 year treatment (X = 3.74 ±0.67) (t = 2.50, p < 0.05). While the difference of the average level of change in disease activity after one and a half years biological treatment (X = 3.86 ±0.80) was significantly higher than after six months of treatment (M = 3.46 ±0.81) (t = 2.28, p < 0.05). The differences between the average level of disease activity after six months of treatment (X = 3.67 ±0.81) and after two years of treatment (X = 3.98 ±0.64) (t = 1.61, p > 0.05) were insignificant.
Conclusions: Biological treatment of children with JIA causes a significant change in disease activity in the objective assessment, bringing beneficial therapeutic effects.
Material and methods: The study was conducted on 33 children before and after switching to etanercept treatment in periods: after 6 months (33 children), after 1 year (24 children), after 1.5 years (18 children) and after 2 years (13 children). Index Disease Activity Score DAS28, a method of diagnostic survey and a systematic analysis of medical records of patients who were enrolled in the biological treatment program were used to examine.
Results: The analysis showed that prior to treatment the children suffering from JIA revealed a significantly higher average level of disease activity (X = 5.82 ±0.77) than in the 6 month period of treatment (X = 2.65 ±1.03) (t = 22.48, p < 0.001). In addition, it has been demonstrated that disease activity of children with JIA after six months of biological treatment (X = 3.33 ±0.77), was significantly lower than after 1 year treatment (X = 3.74 ±0.67) (t = 2.50, p < 0.05). While the difference of the average level of change in disease activity after one and a half years biological treatment (X = 3.86 ±0.80) was significantly higher than after six months of treatment (M = 3.46 ±0.81) (t = 2.28, p < 0.05). The differences between the average level of disease activity after six months of treatment (X = 3.67 ±0.81) and after two years of treatment (X = 3.98 ±0.64) (t = 1.61, p > 0.05) were insignificant.
Conclusions: Biological treatment of children with JIA causes a significant change in disease activity in the objective assessment, bringing beneficial therapeutic effects.
REFERENCES (14)
1.
Tuszkiewicz-Misztal E, Olesińska E. Postępy w reumatologii dziecięcej w 2005 i 2006 roku. Med Prakt Pediatr 2007; 3. .
2.
Filipowicz-Sosnowska A. Skuteczność i bezpieczeństwo inhi-bitorów TNF – wyniki długotrwałych badań obserwacyjnych. Reumatologia 2007; 45: 32-39. .
4.
Santos MJ, Fonseca JE, Canhäo H, et al.; Pelo Grupo de Trabalho de Reumatologia Pediátrica da Sociedade Portuguesa de Reumatologia. Guidelines for prescribing and monitoring biologic therapies in juvenile idiopathic arthritis. Acta Reumatol Port 2007; 32: 43-47. .
5.
Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763-769. .
6.
Hung JJ, Huang JL. Etanercept therapy in children with juvenile rheumatoid arthritis. J Microbiol Immunol Infect 2005; 38: 444-446. .
7.
Lovell DJ, Giannini EH, Reiff A, et al.; Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Pediatric Rheumatology Collaborative Study Group. Arthritis Rheum 2003; 48: 218-226. .
8.
Russo RA, Katsicas MM, Zelazko M. Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol 2002; 20: 723-726. .
9.
Horneff G, Schmeling H, Biedermann T, et al.; Paediatric Rheumatology Collaborative Group. The German etanercept registry for treatment of juvenile idiopathic arthritis. Paediatric Rheumatology Collaborative Group. Ann Rheum Dis 2004; 63: 1638-1644. .
10.
Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48: 1093-1101. .
11.
Kimura Y, Pinho P, Walco G, at al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005; 32: 935-942. .
12.
Petrie A, Sabin C. Błędy w testowaniu hipotez. W: Statystyka medyczna w zarysie. Moczko J (red. wyd. pol.). Wydawnictwo Lekarskie PZWL, Warszawa 2006; 46-47. .
13.
Kietz DA, Pepmueller PH, Moore TL. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 2002; 61: 171-173. .
14.
Lovell DJ, Reiff A, Jones OY, et al.; Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. Arthritis Rheum 2006; 54: 1987-1994.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
